The leading strategy towards eradication of human immunodeficiency virus (HIV) infection is the depletion of viral reservoirs through reversal of viral latency, followed by clearance of persistently infected cells. To date, a latency reversing agent (LRA) that reactivates a majority of the quiescent provirus population, without significant off-target effects, has not been identified. We show here that molecules mimicking the active N-terminal tetrapeptide of the second mitochondrial-derived activator of caspases (SMACm) potently reverse HIV latency in vitro and ex vivo without the pleotropic cellular effects seen with other LRA. We verified that SMACm facilitate latency reversal through activation of the non-canonical 
Introduction
While antiretroviral therapy (ART) has greatly reduced the mortality and morbidity in HIV-infected patients, a functional or sterilizing cure remains elusive. A persistent reservoir of latently infected cells remains during ART, and viremia usually returns within a few weeks following cessation of ART (1) . This reservoir decays slowly, with a half-life of 43 to 44 months (2, 3) , making viral eradication unlikely despite decades of ART. As such, strategies to accelerate decay of the reservoir are under intense investigation.
One such strategy aims to reverse HIV latency, induce proviral RNA and protein expression, and render the formerly latently infected cells vulnerable to viral cytopathic effects or clearance by the immune system (4) . To date, concerns that current latency reversing agents (LRA) tested in vivo may fail to act on the majority of quiescent HIV proviruses or may do so at the cost of significant off-target effects have constrained testing of LRA in vivo.
LRA studied to date rely on either broad activation of cellular pathways such as NFκB, MAPK, and calcineurin (5, 6) , or modification of repressive epigenetic marks on chromatin around the latent provirus (7) (8) (9) (10) (11) . However, these mechanisms have pleiotropic cellular and systemic effects, and lack selectivity for reactivation of HIV. Recently, the targeting of the non-canonical NFκB (ncNFκB) pathway to reverse latency in cell line models was reported (12) . The ncNFκB pathway is typically activated by ligation of a subset of TNF receptor family members (13) . In the steady state, a multimolecular complex with ubiquitin ligase activity consisting of TNF receptor-associated factor 2 (TRAF2), TRAF3, and cellular inhibitor of apoptosis protein-1 (cIAP1) associates with the cytoplasmic portion of the unligated receptor and constitutively ubiquitinylates and degrades the NFκB-inducing kinase (NIK). Upon receptor ligation, cIAP1 ubiquitinylates TRAF3 and auto-ubiquitinylates, leading to proteasomal degradation of TRAF3 and cIAP1, thereby disinhibiting NIK accumulation. NIK is constitutively active and, once accumulated, phosphorylates the inhibitor of κB kinase-α (IKKα) homodimer. The activated IKKα/IKKα homodimer then phosphorylates the inactive p100 form of NFκB2 leading to ubiquitinylation by Skp1-Cul1-F-box ubiquitin ligase (SCF βTrCP ) and proteasomal cleavage of p100, releasing the active p52 subunit. p52 associates with RelB, and this heterodimer translocates into the nucleus to drive transcription from κB promoter elements.
In addition to receptor ligation, ncNFκB can be activated by signaling intermediates of the apoptosis cascade (14, 15) . to the BIR domains of XIAP and ML-IAP antagonizes the caspase inhibition activities of these molecules, often overexpressed in tumor cells, leading to potentiation of apoptosis (17) (18) (19) . As such the Ala-Val-ProIle motif of SMAC has been the subject of significant attention in oncology, leading to discovery of a class of peptide mimetics that have SMAC-like activity, referred to as SMAC mimetics (SMACm). SMACm potently activate the ncNFκB pathway and do not induce apoptosis in non-tumor cells, and as such are of interest to reverse HIV latency (12) .
Here we demonstrate that the SMACm AZD5582 functions alone as a potent LRA in vitro and ex vivo while, in contrast to other well-studied LRA, having limited additional effects on CD4+ T cells. Using a Jurkat reporter cell line model of latency, we show that several members of a panel of commercially available
SMACm reverse HIV latency. Potent SMACm were confirmed to engage cIAP1 and activate the ncNFκB pathway in primary CD4+T cells. Furthermore, AZD5582 treatment had minimal impact on global gene expression in isolated CD4+ T cells. Exposure of total and resting CD4+T cells from ART-suppressed, HIVinfected subjects to AZD5582 led to a significant increase in cell-associated full-length HIV RNA (caRNA).
Moreover, ex vivo AZD5582 exposure at durations and concentrations achievable in vivo led to engagement of cIAP1, activation of ncNFκB, and induction of caRNA. In sum, our work demonstrates that SMACm have HIV latency reversal activity with minimal off-target effects and therefore should be evaluated in preclinical models as part of an HIV cure strategy.
Results

ncNFκB activation by SMACm and minimal NIK reverses HIV latency in vitro
The potential for SMACm to reverse HIV latency via the ncNFκB pathway was first suggested in studies of cell-line models of latency (12) . We sought to validate and extend these findings, and to this end characterized the HIV latency reversing activity of a panel of commercially available SMACm. We first tested these molecules in an assay using a pool of three selected clones of Jurkat cells that demonstrated quiescent but inducible viral expression following infection with an HIV NL4-3 engineered with a bicistronic reporter consisting of luciferase and murine heat shock antigen (mHSA) in place of nef (Irlbeck, manuscript in preparation). Dimeric SMACm such as BV6, birinapant, SM-164, and AZD5582 demonstrated the strongest combination of luciferase induction in terms of maximum level (Vmax) and potency (pEC50) amongst the panel of SMACm tested, greatly exceeding the reporter induction of comparable monomeric compounds AT406, GDC-0152, and LCL161 ( Fig.1A and Table 1 ). Examination of the kinetics of reporter expression demonstrated that SMACm-mediated induction of luciferase was slower and less strong than that observed with canonical NFκB activating agents (Fig.1B) . For example the PKC agonist GSK445, a stabilized ingenol B derivative (manuscript in preparation and ref. (20) ), induced luciferase activity that peaked approximately 24 hours after exposure at 35-fold higher than DMSO alone and quickly waned, while AZD5582-induced activity plateaued at 24 hours after exposure at approximately 15-fold higher than DMSO and was sustained near that level for up to 72 hours (Fig.1B) .
To confirm that HIV latency reversal could be achieved through the activation of the ncNFκB pathway without SMACm, we infected a single clone of the latent HIV-infected Jurkat reporter cell described above with a lentiviral vector encoding eGFP and minimal NIK (mNIK). This mNIK construct lacks the N-terminal TRAF3 binding domain of NIK responsible for interaction with the TRAF3:TRAF2:cIAP1 complex and ubiquitin mediated degradation of NIK. In turn, mNIK accumulates and, as NIK is constitutively active, ncNFκB activation occurs (21, 22) . Infection with the vector encoding both eGFP and mNIK led to spontaneous HIV LTR-driven murine HSA reporter expression among the GFP+ cells as compared to uninfected cells (GFP-) in the same culture or to cells infected with a control vector lacking mNIK (Fig.1C) .
Moreover, combining mNIK infection with exposure to the bromodomain inhibitor, iBET151, led to synergistic reporter activation in the GFP+ cells, but not GFP-cells (Fig.1C) .
As SMACm were initially developed to potentiate apoptosis, we studied the impact of the most potent SMACm tested, AZD5582, on cellular viability in cell lines and primary cells. Using a luciferase-based assay for quantifying ATP content, we found that AZD5582 did not significantly impact viability of Jurkat cells.
However, addition of a sub-cytotoxic concentration of TNFα (10ng/mL) led to AZD5582 dose-dependent cell death in Jurkat cells, with a CC50 comparable to that observed for AZD5582 LRA activity in the Jurkat reporter cells (Fig.1D ), as described for SMACm and TNF exposure in other transformed cell lines (23) .
AZD5582 had minimal impact on cellular viability in PBMC and addition of TNFα did not potentiate cell death, in contrast to what was observed for Jurkat cells (Fig.1D ). Similar to total PBMC, SMACm did not lead to overt cell death among isolated total CD4+ T cells (Fig.1E ) or resting CD4+ T cells (Fig.1F) , though a consistent decrease in ATP levels (approximately 80% of DMSO treated cells) was observed among total CD4+ T cells (Fig.1E ). Together these findings confirm earlier reports that SMACm can reverse HIV latency in cell line models and do not have a significant impact on viability in primary cells.
Kinetics and dose-dependent activation of the ncNFκB pathway by SMACm
To confirm engagement of the ncNFκB pathway by SMACm, we assessed depletion of the proximal SMACm target proteins -cIAP1 and cIAP2 -and downstream processing of p100 to p52 in primary CD4+
T cells exposed to AZD5582. Immunoblot analysis showed rapid and durable depletion of cIAP1, and to a lesser extent cIAP2, within 30 minutes of exposure to 100nM AZD5582 ( Fig.2A) . Although cIAP1 and cIAP2 depletion occurred rapidly, processing of p100 to p52 was not observed until 4 hours post-exposure and accumulated over 48 hours of exposure, with final p52 levels greater than 10-fold higher than observed before treatment (Fig.2B) . The canonical NFκB pathway was not activated by AZD5582, as evidenced by maintenance of IκBα, and instead IκBα protein levels increased over time during AZD5582 exposure (Fig.2B ). The depletion of cIAP1 and conversion of p100 to p52 by AZD5582 was dose dependent, with cIAP1 depleted and p100 cleaved at concentrations exceeding 0.1nM. Despite dose dependent depletion of cIAP1 in primary CD4+ T cells comparable to that observed with AZD5582, cleavage of p100 into the active p52 was only observed at birinapant exposures greater than 100nM ( Fig.2D-E) . The full activation of ncNFκB, as measured by p100 to p52 conversion, by AZD5582 at comparable concentrations to those where HIV latency is reversed supports the conclusion that the latency reversal activity is mediated through ncNFκB activation.
Short duration exposure to AZD5582 activates the ncNFκB pathway and reverses HIV latency
AZD5582 is cleared from circulation rapidly; relevant in vivo doses are estimated to achieve only one to two hours of plasma exposure at concentrations greater than the EC50 (24) . To study whether such brief exposure supports latency reversal, we treated cells with AZD5582 for short periods of time followed by extensive washing to remove the drug and measured ncNFκB pathway activation over time by western blot. In primary CD4+ T cells, as short as one hour exposure to 100nM AZD5582 was sufficient to deplete cIAP1 and cIAP2 and induce processing of p100, with the densitometric ratio of p52 to p100 in western blot achieving greater than 60% of that observed with continuous exposure (Fig.3A-E) . Similarly, exposure of the Jurkat reporter cells for as little as 30 minutes to AZD5582 led to induction of luciferase activity comparable with that observed with continuous AZD5582 exposure (Fig.3F ). These pulse-wash studies demonstrate that exposure to SMACm at intervals and concentrations achievable in vivo can activate ncNFκB and reverse HIV latency.
AZD5582 has minimal impact on activation or gene expression in CD4+ T cells.
Classical latency reversal is achieved by maximal T-cell activation using agents such as anti-CD3/anti-CD28
or protein kinase C agonist (PKCa). These molecules induce strong activation signatures in T cells and initiate substantial changes in gene expression. To test whether SMACm have similar activity, we first measured CD69 expression in primary T cells exposed to AZD5582. We found no induction of CD69 in CD4+ T cells cultured for 24 hours in the continuous presence of up to 1000nM AZD5582 (Fig.4A ). We then characterized the transcriptome of isolated CD4+ T cells treated with 100nM AZD5582 or 250nM the PKCa GSK445A (20) to better understand the global transcriptional impact of SMACm. We performed unbiased, stranded mRNA sequencing from total RNA extracted from total CD4+ T cells isolated from four ARTsuppressed, HIV-infected donors. If, like in classical latency reversal approaches, AZD5582 treated cells evinced a strong change in gene expression, this would suggest that AZD5582 has a strong activation signature and potentially collateral effects on the cell. Instead, AZD5582 exposure led to relatively few differentially expressed genes when compared to vehicle (upregulated genes: 27 at 2hrs, 134 at 6hrs, 387 at 24hrs), while GSK445A led to differential expression of nearly 100-fold more genes (upregulated genes:
2643 at 2hrs, 2902 at 6hrs, 2303 at 24hrs) ( Fig.4B ). AZD5582 treatment primarily led to increases in gene expression, as compared to a relative balance of increased and decreased expression after GSK445A exposure ( Fig.4B ). In agreement with the slow, durable kinetics of p100 processing described above, the number of genes affected by AZD5582 increased over time, and only 15 genes activated at 2 and 6 hours
were not up-regulated at 24 hours (Fig.4D ). Among the genes induced by AZD5582 at any timepoint, more than half were also induced by GSK445A (Fig.4C ). Gene ontology analysis of the shared 87 induced genes at 6 hours showed enrichment for NFκB-related pathways (Fig.4E ), while no enrichment was identified for the remaining 47 genes induced by AZD5582 alone. This analysis suggests that HIV latency reversal by SMACm does not require full T-cell activation and occurs in the context of orders of magnitude fewer genes than those induced by T-cell activation by PKCa.
AZD5582 can increase viral transcripts from patient total and resting CD4+ T cells ex vivo
To understand whether potent SMACm can act as LRA in patient-derived cells, we measured total full length HIV RNA levels using quantitative PCR with primers targeting gag (herein referred to as caRNA) in isolated total CD4+ T cells from ART-suppressed HIV-infected donors treated with SMACm ex vivo ( Table   2 ). We observed up to a 2.2-fold induction of caRNA in at least one condition tested in six of the ten donors ( T cells (Fig.2D-E) . In the cells from the four donors in which caRNA was not induced by AZD5582, baseline caRNA levels were at or near the limit of quantification for the PCR assay in all conditions (7 copies per reaction), or caRNA induction was not observed following maximal PMA/Ionomycin treatment, indicating that induction may have occurred but was below the limit of detection (Supplemental Fig.1A ). When the data from all ten donors was considered in aggregate, statistically significant induction was observed as low as 31.6nM (p<0.01, Fig.5A ).
Total CD4+ T cells are more likely to contain cells that are producing HIV RNA directly ex vivo and stimulation may simply increase this pre-existing HIV RNA expression, complicating the interpretation of caRNA induction by putative LRA. We therefore specifically examined isolated resting CD4+ T cells, in which baseline levels of caRNA are lower and which likely contain a more resistant subpopulation of latently infected cells. Indeed, it is this population that has been shown to be stable despite years of ART can reverse HIV latency in primary patient-derived cells, we exposed patient-derived total or resting CD4+
T cells to 100nM AZD5582 for one hour and measured caRNA 48 hours later. In the three samples tested, one hour exposure to 100nM consistently increased caRNA to levels comparable with 48-hour continuous exposure (Fig.5C ). These data represent the first demonstration that SMACm alone can reverse HIV latency ex vivo in resting CD4+ T cells from stably ART-suppressed donors.
Discussion
While several LRA have shown efficacy in in vitro and ex vivo experiments, the most potent of these compounds have significant collateral effects on the host cells such as overt T-cell activation and/or broad cytotoxicity. Here we demonstrate that a SMACm, AZD5582, reverses HIV latency through the activation of the ncNFκB pathway without evidence of host cell activation and with minimal host cell transcriptional changes. Moreover, we demonstrate that AZD5582 activates the most quiescent proviral reservoir of the resting CD4+ T cells at concentrations and exposure durations that are achievable in preclinical animal models.
In our initial screen of SMACm using a Jurkat reporter model of HIV latency, we observed a range of potencies across this class of compounds ranging from completely inactive (AEG40730) to an EC50 of 7.5nM (AZD5582) (Fig.1A) . The bivalent SMACm compounds demonstrated higher activity and potency than did their monovalent counterparts. Based on immunoblot studies, we found that AZD5582 potently induces degradation of cIAP1 at sub-nanomolar concentrations (Fig.2D ) and induces degradation of cIAP2 to approximately 50% of its pre-treatment levels ( Fig.2A) , comparable to reported cell-free BIR domain binding activity (25) and our observed EC50 in the Jurkat model (Fig.1A) . These findings confirm previous reports (12) and support the conclusion that SMACm activate the ncNFκB pathway to reverse HIV latency.
Unlike other potent LRA that typically activate rapid and potent mechanisms, SMACm led to slow and durable activation of ncNFκB, as evidenced by conversion of p100 to active p52 starting 2 to 4 hours posttreatment and continuing for at least 48 hours post-treatment (Fig.2B-C) . The activation kinetics observed in this study are in line with other reports of ncNFκB activation by SMACm and generally support a less frequent dosing regimen (e.g., once or twice weekly) as has been utilized in SMACm preclinical and clinical studies (25, 26) . Moreover, the durable activation of ncNFκB and observed HIV latency reversal despite limited duration exposure to SMACm (Fig.3 and Fig.5C ) further boost confidence in increased dosing intervals in future in vivo experiments. It will be important in the future to investigate how long ncNFκB remains activated following SMACm exposure and how such activation is resolved, as these parameters will be key in determining optimal dosing intervals in preclinical and clinical studies for HIV cure.
In contrast to the transcriptional signature of PKCa, SMACm were demonstrated here to have relatively minimal impact on T-cell activation or host transcriptome (Fig.4) . Even when comparing timepoints at which the most genes were induced for each treatment (6 hours for PKCa vs. 24 hours for SMACm), the PKCa GSK445A induced 7.5-fold more genes than AZD5582 (Fig.4C) . This limited modulation of host gene expression induced by AZD5582, along with the lack of induction of T-cell activation markers (Fig.4A) demonstrates that AZD5582 is more selective for induction of HIV transcriptional activity and may therefore be expected to have more limited collateral effects than other agonist LRA, such as PKCa. While these T-cell transcriptomic findings are an important first study in examining the off-target impacts of SMACm, follow-up studies on the effects of SMACm on other cell types, such as monocytes and B cells, will be important to form a more complete understanding of SMACm on and off target activities prior to preclinical and clinical studies.
One key advance shown here is that SMACm can function as a single agent to induce HIV RNA expression in ex vivo treatment of CD4+ T cells isolated from ART-treated, aviremic patients. We observed statistically significant increases in caRNA in total CD4+ T cells as well as the more quiescent and refractory resting CD4+ T-cell population (Fig.5A-B) . Moreover, as little as a one hour exposure to 100nM AZD5582, a concentration and duration achieved in murine oncology models, led to significant increases in caRNA in patient-derived resting CD4+ T cells with fold-increases similar to that observed with continuous exposure (Fig.5C ). This set of ex vivo HIV latency reversing experiments gives the greatest insight into the potential of SMACm in a clinical setting due to the diversity of proviruses and host genetic heterogeneity encompassed in testing patient cells.
In this study, we show that the potent SMACm AZD5582 activates ncNFκB and reverses HIV latency in cell line models of HIV latency and in patient-derived resting CD4+ T cells, while modulating expression of only a limited number of host genes. Importantly, the ex vivo ncNFκB activation and LRA activity are induced with AZD5582 concentrations and durations of exposure that are achievable in preclinical models. In sum, our work demonstrates that SMACm are an important novel LRA specifically activating the ncNFκB pathway that may accelerate decay of the HIV reservoir as part of an HIV cure strategy. These studies therefore set the stage for preclinical evaluation of SMACm in animal models of HIV latency.
Methods
Preparation of Jurkat HIV-luciferase cell clones
Cell clones Jurkat-C16 and Jurkat-I15 were made using HIV-1 engineered to express a luciferase reporter in place of the HIV-1 nef gene (NLCH-Luci). The Jurkat-N6 cell clone was made using the same virus as Luminescence resulting from the induction of the virally expressed luciferase was measured using an EnVision 2102 Multilabel Plate Reader (Perkin Elmer, Shelton, CT). Dose-response relationships were analyzed with GraphPad PRISM 6 using a four-parameter model to calculate the concentration of compound that gives half-maximal response (EC50) and the maximal percent activation compared to the vehicle control (Vmax).
Minimal NIK Construction
Coding sequence for amino acids 330-679 corresponding to the catalytic core of NIK (mNIK) HIV absolute HIV gag RNA copies per reaction were determined using an HIV gag gBlock qPCR standard
Integrated DNA Technologies), and copies were normalized to cell counts as determined by bright field microscopy. RT-qPCR efficiency was required to be between 90% to 110%. Assay values with a positive signal that were less than the lower limit of detection (LLOD) of seven HIV gag copies per reaction were adjusted to the LLOD. Analysis was performed using QuantStudio™ Design and Analysis Software (Applied Biosystems) and JMP 12.2 Statistical Discovery™ software (SAS).
Immunoblot Analysis
For the immunoblot assays, 10 µg of cell lysate was loaded per well into 4-20% Tris-Glycine SDS-PAGE gels.
Protein from the SDS-PAGE gels were transferred to Turbo Midi PVDF Transfer Packs (BioRad) using the The stripped membranes were then blocked in 5% BSA in 1x TBS+0.1% TWEEN® 20 for an hour and reprobed overnight with a new primary antibody.
Flow Cytometry
Cryopreserved PBMC were thawed, plated, and exposed to a dose range of AZD5582 or GSK445A. After Raw reads were mapped to the human genome and transcriptome (GRCh38.p7) using STAR and Salmon (28) . Data was normalized and interrogated for changes in gene expression using DESeq2 (29) package in R. P-values were adjusted for multiple testing using a false discovery rate using the Benjamini-Hochberg method (30) . Data was analyzed both jointly and within each treatment compared to the vehicle control.
Differential expression of outliers was assessed and found insignificant in overall effect. Graphs and summary tables were built in R using ggplot. Gene set enrichment was performed using GSEA and GO analysis (31) .
Statistics
Statistical analysis was carried out using the pairwise, nonparametric Wilcoxon method and statistical significance was assigned to p-values of less than 0.05.
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